G1 Therapeutics (NASDAQ:GTHX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Monday.
According to Zacks, “G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company’s product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. “
Several other research firms have also commented on GTHX. BidaskClub raised shares of G1 Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. JPMorgan Chase & Co. upped their price target on shares of G1 Therapeutics to $30.00 in a report on Monday, February 5th. Cowen reaffirmed a “buy” rating on shares of G1 Therapeutics in a report on Wednesday, November 8th. Finally, BTIG Research began coverage on shares of G1 Therapeutics in a report on Tuesday, December 19th. They issued a “buy” rating and a $38.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. G1 Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $32.80.
G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings data on Wednesday, February 21st. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.02). analysts predict that G1 Therapeutics will post -2.48 EPS for the current fiscal year.
In other G1 Therapeutics news, insider Rajesh Malik sold 3,776 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $22.96, for a total value of $86,696.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Medimmune Ventures, Inc. sold 200,000 shares of the company’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $19.75, for a total transaction of $3,950,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 350,458 shares of company stock worth $6,939,148.
Several institutional investors have recently modified their holdings of the business. Teachers Advisors LLC raised its position in shares of G1 Therapeutics by 44.6% in the fourth quarter. Teachers Advisors LLC now owns 13,818 shares of the company’s stock worth $274,000 after acquiring an additional 4,260 shares during the period. Two Sigma Investments LP acquired a new position in shares of G1 Therapeutics in the fourth quarter worth about $493,000. Ellington Management Group LLC acquired a new position in shares of G1 Therapeutics in the fourth quarter worth about $294,000. Goldman Sachs Group Inc. raised its position in shares of G1 Therapeutics by 237.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 28,308 shares of the company’s stock worth $562,000 after acquiring an additional 19,923 shares during the period. Finally, Deutsche Bank AG raised its position in shares of G1 Therapeutics by 171.6% in the fourth quarter. Deutsche Bank AG now owns 19,208 shares of the company’s stock worth $380,000 after acquiring an additional 12,136 shares during the period. Institutional investors and hedge funds own 52.01% of the company’s stock.
About G1 Therapeutics
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.